 This research focused on developing a novel drug delivery system for transungual administration of turbinifine, TBF. The developed formulation, TBFIN, consists of TBF entrapped within lanallol, containing vesicles. The vesicles are produced by the ThinFilm hydration method and optimized using the BoxBanken design, BBD. The vesicles have a smaller size, higher entrapment efficiency and lower polydispersity index compared to other vesicular systems. Furthermore, the TBFIN formulation has improved antifungal activity against both tricophyton rubrum and candida albicans. Additionally, the TBFIN formulation is safe for topical application and does not cause any skin irritation when tested on Wista albino rats. Overall, this study demonstrates that the TBFIN formulation is an effective vehicle for transungual delivery of TBF for the treatment of onicomycosis. This article was authored by Isha Gupta, Saida Nashveya Aidan, and Diabdur Rashid, and others.